Epidarex

Epidarex Capital – Catalyzing innovation in health science and technology

Epidarex Capital Leads New Investment in Edinburgh Molecular Imaging

Edinburgh, United Kingdom, February 7, 2014.  Epidarex Capital, a leading international early-stage life science venture capital fund, has announced a £4 million Series A investment, in Edinburgh Molecular Imaging (EMI). Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round. EMI, an…

The following articles make reference to Epidarex Capital under its previous name.

Apellis Pharmaceuticals Inc. Raises Series C Financing

Louisville, Kentucky – August 21st, 2013 – Rock Spring Ventures has increased its investment in Apellis Pharmaceuticals Inc., an early-stage biotechnology company focused on developing a novel pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development. Apellis…

New £50M Fund Will Support Life Science Sector

Edinburgh, United Kingdom – January 21st 2013 – Rock Spring Ventures today launched a unique £50m venture capital fund focusing on early-stage life science and health technology companies. Based in Scotland, the fund will invest in young companies developing novel approaches to unmet needs in…